EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies

Gerard J Criner iD, Dave Singh iD, Alberto Papi iD, Maria Jison, Natalya Makulova, Vivian H Shih, Laura Brooks, Peter N Barker, Ubaldo J Martin

Therapeutic Advances in Respiratory Disease · 2025

DOI: 10.1177/17534666241312060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Gerard J Criner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Antibodies, Monoclonal, Humanized, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

What is this summary about? ● This is a plain language summary of two articles originally published in The New England Journal of Medicine and The Lancet Respiratory Medicine . These articles presented the results of GALATHEA and TERRANOVA, two clinical studies that took place across 41 countries. ○ GALATHEA and TERRANOVA measured how patients’ COPD changed from before their first benralizumab (10, 30, or 100 mg) injection, to after 56 weeks of treatment. ○ In both studies, benralizumab was compared with placebo . ○ To see whether benralizumab treatment would benefit any particular patients included in these studies, researchers carried out an additional analysis following the main studies of GALATHEA and TERRANOVA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveAntibodies, Monoclonal, HumanizedLungHumansTreatment OutcomeRandomized Controlled Trials as TopicDose-Response Relationship, DrugPlain Language Summaries

Stichwörter der Autor:innen

GALATHEATERRANOVAbenralizumabbiologicchronic obstructive pulmonary diseaseeosinophilinterleukin-5

Substanzen

benralizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
  • Clinical Pharmacology and Respiratory Medicine, University of Manchester, Medicines Evaluation Unit, Manchester University Foundation Hospitals Trust, Manchester, UK.
  • Respiratory Medicine, University of Ferrara, Ferrara, Italy.
  • Department of Emergency Medicine, Respiratory Unit, S. Anna University Hospital, Ferrara, Italy.
  • Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Gerard J Criner, Dave Singh, Alberto Papi

Förderung

  • AstraZeneca

Zitieren

APA

Criner, G. J., Singh, D., Papi, A., Jison, M., Makulova, N., Shih, V. H., Brooks, L., Barker, P. N., & Martin, U. J. (2025). Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241312060

Vancouver

Criner GJ, Singh D, Papi A, Jison M, Makulova N, Shih VH, et al. Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666241312060

BibTeX
@article{Criner2025,
  author = {Criner, Gerard J and Singh, Dave and Papi, Alberto and Jison, Maria and Makulova, Natalya and Shih, Vivian H and Brooks, Laura and Barker, Peter N and Martin, Ubaldo J},
  title = {Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  doi = {10.1177/17534666241312060}
}
Kostenlos starten →